Watson Strides into Australian, SE Asian generics markets with $393m Ascent
This article was originally published in Scrip
Watson Pharmaceuticals has snapped up Strides Arcolab's Australian and Southeast Asian generics business for Aus$375 million ($393 million), catapulting the US firm to fifth position in the growing Australian generics market by revenue and giving it the top slot in Singapore.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.